David Hallal brings his first cell therapy company into the fold, and it's tied to a major league financing deal
David Hallal wasn’t kidding around when he said that his startup ElevateBio was ready to do business.
The ex-Alexion CEO is unveiling his first portfolio deal for his $150 million cell and gene therapy startup ElevateBio this morning. And it’s tied into a major league financing round that puts Hallal’s team right on the threshold of a Phase III campaign, with an immediate need to ramp up manufacturing and start laying the foundation for potential commercial work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.